Overall | Price groups | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model | Model 0 | Model 1 | Model 2 | Model 3 | Model 3b | Model 1 | Model 2 | Model 3 | ||||||||||||||
Price magnitudec | 100 k$ | 1$ | 100 k$ | 1$ | 100 k$ | 1$ | ||||||||||||||||
Estimates of fixed effects (explanatory) | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. | Est. | sig. |
Intercept | 1.60 | a | 0.41 | – | − 0.01 | – | − 0.15 | – | − 0.15 | – | 0.59 | – | 0.58 | – | 0.40 | – | 0.24 | – | − 0.01 | – | 0.55 | – |
Survival | 0.13 | a | 0.15 | a | 0.15 | a | 0.15 | a | 0.11 | a | 0.13 | a | 0.13 | a | 0.14 | a | 0.13 | a | 0.14 | a | ||
ROLE GROUP [=0]d | 0.26 | b | 0.26 | b | 0.22 | – | 0.22 | – | −0.11 | – | 0.28 | b | −0.23 | – | 0.31 | b | −0.22 | – | 0.30 | b | ||
PRICE GROUP [=0] | 0.37 | a | 0.40 | a | 0.36 | a | 0.36 | a | ||||||||||||||
RANK Patient | −0.01 | – | −0.02 | – | 0.03 | – | ||||||||||||||||
RANK Premium payers | −0.05 | – | −0.01 | – | −0.00 | – | − 0.00 | – | −0.06 | – | − 0.05 | – | −0.01 | – | − 0.01 | – | −0.00 | – | − 0.03 | – | ||
RANK Investors | −0.06 | – | −0.04 | – | − 0.03 | – | −0.04 | – | − 0.06 | – | −0.06 | – | − 0.03 | – | −0.07 | – | − 0.01 | – | −0.10 | – | ||
RANK Own role | −0.05 | – | 0.02 | – | −0.11 | – | ||||||||||||||||
RANK Negotiation partner | 0.00 | – | 0.08 | – | 0.07 | – | 0.07 | – | 0.00 | – | 0.00 | – | 0.10 | – | 0.05 | – | 0.10 | – | 0.01 | – | ||
Stakeholder No1 (Patient = 0, self = 1) [=0] | −0.12 | – | −0.04 | – | −0.04 | – | 0.02 | – | −0.29 | – | 0.08 | – | −0.21 | – | ||||||||
ROLE GROUP [=0] × PRICE GROUP [=0] | −0.35 | b | −0.48 | a | −0.39 | b | −0.39 | b | ||||||||||||||
ROLE GROUP [=0] × Survival | −0.00 | – | 0.00 | – | 0.00 | – | −0.01 | – | − 0.01 | – | 0.00 | – | − 0.00 | – | 0.01 | – | − 0.00 | – | 0.01 | – | ||
PRICE GROUP [=0] × Survival | −0.02 | b | −0.02 | b | −0.02 | b | −0.02 | b | ||||||||||||||
Stakeholder No1 [=0] × Survival | −0.02 | b | −0.02 | b | −0.03 | b | −0.01 | – | −0.03 | b | −0.01 | – | ||||||||||
Stakeholder No1 [=0] × ROLE [=0] × Survival | −0.01 | – | ||||||||||||||||||||
Stakeholder No1 [=1] × ROLE [=0] × Survival | −0.03 | b | ||||||||||||||||||||
Estimates of fixed effects (control variables) | ||||||||||||||||||||||
Performance: attention screening question | 0.26 | a | 0.26 | a | 0.20 | – | 0.31 | b | ||||||||||||||
Performance: comprehension question 4 | −0.01 | – | −0.01 | – | 0.07 | – | −0.03 | – | ||||||||||||||
Health experience & risk behaviour | X | X | X | X | ||||||||||||||||||
Demographics | X | X | X | X | X | X | X | X | X | X | ||||||||||||
Estimates of covariance parameters | ||||||||||||||||||||||
Residual | 0.29 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a | 0.01 | a |
Intercept [subject]e, Variance | 0.50 | a | 0.39 | a | 0.36 | a | 0.33 | a | 0.33 | a | 0.38 | a | 0.37 | a | 0.33 | a | 0.36 | a | 0.30 | a | 0.33 | a |
Survival [subject], Variance | 0.01 | a | 0.00 | a | 0.00 | a | 0.00 | a | 0.00 | a | 0.01 | a | 0.00 | a | 0.01 | a | 0.00 | a | 0.01 | a | ||
Model summary | ||||||||||||||||||||||
Observations: price statements (participants) | 1190 | (238) | 1190 | (238) | 1020 | (204) | 1020 | (204) | 1020 | (204) | 610 | (122) | 580 | (116) | 525 | (105) | 495 | (99) | 525 | (105) | 495 | (99) |
Intraclass correlation (ICC)e | 0.63 | 0.97 | 0.97 | 0.96 | 0.96 | 0.97 | 0.96 | 0.97 | 0.96 | 0.97 | 0.96 | |||||||||||
Proportional reduction of error term (R2)f | 0.49 | 0.53 | 0.56 | 0.56 | 0.50 | 0.51 | 0.56 | 0.51 | 0.61 | 0.56 | ||||||||||||
R2 level 1g | 0.96 | 0.96 | 0.96 | 0.96 | 0.96 | 0.95 | 0.96 | 0.95 | 0.96 | 0.95 | ||||||||||||
R2 level 2h | 0.22 | 0.28 | 0.33 | 0.33 | 0.23 | 0.26 | 0.33 | 0.26 | 0.40 | 0.34 | ||||||||||||
Model description | ||||||||||||||||||||||
preferences | X | X | X | X | X | X | X | X | X | X | ||||||||||||
patient orientation | X | X | X | X | X | X | X | |||||||||||||||
performance & personality | X | X | X | X |